Now More Men with Metastatic Castration-Resistant Prostate Cancer May Benefit from Treatment with ZYTIGA®
ZYTIGA® plus prednisone is used to treat men who have castration-resistant prostate cancer (defined as prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has spread to other parts of the body (mCRPC).
If you're living with metastatic castration-resistant prostate cancer, your treatment journey to this point has probably been a difficult one. Whether you're the patient or the caregiver, you may be wondering about where to go from here.
What Can ZYTIGA® Do for Me?
In a new study of men with metastatic castration-resistant prostate cancer who had not received chemotherapy:
- Certain men treated with ZYTIGA® plus prednisone lived longer than men treated with placebo plus prednisone (median overall survival was 35.3 months for men treated with ZYTIGA® plus prednisone compared with 30.1 months for men treated with placebo [sugar pill] plus prednisone). However, the difference was not statistically significant.
- ZYTIGA® plus prednisone increased the length of time certain men lived with the disease but did not get worse as measured by imaging studies1 (i.e., bone scans). One hundred fifty of 546 men (28%) treated with ZYTIGA® plus prednisone and 251 of 542 men (46%) treated with placebo (sugar pills) plus prednisone had disease progression.
- ZYTIGA® plus prednisone significantly delayed the median time to starting chemotherapy (25.2 months for patients receiving ZYTIGA® plus prednisone and 16.8 months for patients receiving placebo [sugar pill] plus prednisone).
ZYTIGA® can also be used in men with mCRPC who have received chemotherapy with docetaxel
Results from a clinical trial showed that certain men with mCRPC* who had received chemotherapy with docetaxel and who were treated with ZYTIGA® plus prednisone lived longer than men who were treated with placebo (sugar pill) plus prednisone. In the clinical trial, the median† survival for men treated with ZYTIGA® plus prednisone was 15.8 months versus 11.2 months for men treated with placebo plus prednisone.
Talk to your doctor about how you may be able to benefit from treatment with ZYTIGA®.
ZYTIGA® may cause serious side effects, including:
High blood pressure (hypertension), low blood potassium (hypokalemia), and fluid retention (edema).
Tell your healthcare provider if you get any of the following symptoms:
Adrenal problems may happen if you stop taking prednisone, get an infection, or are under stress.
Liver problems. You may develop changes in liver function blood test. Your healthcare provider will do blood tests to check your liver before treatment with ZYTIGA® and during treatment with ZYTIGA®.
The most common side effects of ZYTIGA® include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
THESE ARE NOT ALL THE POSSIBLE SIDE EFFECTS OF ZYTIGA®. FOR MORE INFORMATION, ASK YOUR HEALTHCARE PROVIDER OR PHARMACIST.
Please see additional Important Safety Information below.
- 1 "PFS." NCI Dictionary of Cancer Terms. National Cancer Institute, n.d. Web. 11 Dec. 2012.
- † The median is the middle number in a group of numbers (such as overall survival results) that are arranged from lowest to highest. For example, in the group of numbers 1 to 11, 6 is the median.